相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
William R. Schelman et al.
INVESTIGATIONAL NEW DRUGS (2011)
[90Y]Yttrium Microspheres Radioembolotherapy in Desmoplastic Small Round Cell Tumor Hepatic Metastases
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular Remission in Follicular Lymphoma: Is the Era of Residual Disease Monitoring Over?
Vit Prochazka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer
Evan Y. Yu et al.
UROLOGY (2011)
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
G. Sonpavde et al.
ANNALS OF ONCOLOGY (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Bone-specific growth inhibition of prostate cancer metastasis by atrasentan
Justin M. Drake et al.
CANCER BIOLOGY & THERAPY (2010)
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy
P. Mathew et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer
Fred Saad et al.
CANCER TREATMENT REVIEWS (2010)
Targeting the α Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis
Mike R. Russell et al.
CLINICAL CANCER RESEARCH (2010)
Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer
Joanne Edwards
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
The Tyrosine Kinase Inhibitor Dasatinib Dysregulates Bone Remodeling Through Inhibition of Osteoclasts In Vivo
Kate Vandyke et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of the Src Kinase Inhibitor Saracatinib (AZD0530) on Bone Turnover in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Phase I Trial
Rosemary A. Hannon et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Yang-Min Ning et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis In vitro and In vivo through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis
Shafaat A. Rabbani et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts
Y-C Lee et al.
ONCOGENE (2010)
Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054
James W. Growcott
ANTI-CANCER DRUGS (2009)
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study
Primo N. Lara et al.
ANTI-CANCER DRUGS (2009)
SPECIFIC ENDOTHELIN-A RECEPTOR ANTAGONISM FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
Karim Fizazi et al.
BJU INTERNATIONAL (2009)
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis
T. Koreckij et al.
BRITISH JOURNAL OF CANCER (2009)
Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles
Christine J. Weydert et al.
CANCER BIOLOGY & THERAPY (2009)
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation
John C. Araujo et al.
CANCER BIOLOGY & THERAPY (2009)
Aberrant Activation of Androgen Receptor in a New Neuropeptide-Autocrine Model of Androgen-Insensitive Prostate Cancer
Joy C. Yang et al.
CANCER RESEARCH (2009)
Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells
B. Karabulut et al.
CELL BIOLOGY INTERNATIONAL (2009)
Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer
Oleg Tatarov et al.
CLINICAL CANCER RESEARCH (2009)
Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
Nicholas D. James et al.
EUROPEAN UROLOGY (2009)
Targeting Src signaling in metastatic bone disease
John Araujo et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer
Karim Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer
William L. Dahut et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial
Karim Fizazi et al.
JOURNAL OF UROLOGY (2009)
The Src Inhibitor AZD0530 Reversibly Inhibits the Formation and Activity of Human Osteoclasts
Teun J. de Vries et al.
MOLECULAR CANCER RESEARCH (2009)
Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor
N. Brownlow et al.
LEUKEMIA (2009)
Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis
K. Vandyke et al.
LEUKEMIA (2009)
Src kinases as therapeutic targets for cancer
Lori C. Kim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer
C. N. Sternberg
ANNALS OF ONCOLOGY (2008)
Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice
Johanna M. Tuomela et al.
BMC CANCER (2008)
Phase 3, Randomized, Controlled Trial of Atrasentan in Patients With Nonmetastatic, Hormone-Refractory Prostate Cancer
Joel B. Nelson et al.
CANCER (2008)
Immunomodulatory drugs Revlimid (R) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
Dan Zhu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts
Albana Cumashi et al.
CANCER LETTERS (2008)
Targeting src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model
Serk In Park et al.
CANCER RESEARCH (2008)
Antitumor effects of bisphosphonates: Promising preclinical evidence
Theresa A. Guise
CANCER TREATMENT REVIEWS (2008)
Emerging robe of bisphosphonates in the clinic - Antitumor activity and prevention of metastasis to bone
Allan Lipton
CANCER TREATMENT REVIEWS (2008)
A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2008)
Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
Giuseppe Di Lorenzo et al.
EUROPEAN UROLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Thalidomide and lenalidomide: Mechanism-based potential drug combinations
Sonia Vallet et al.
LEUKEMIA & LYMPHOMA (2008)
Bisphosphonates: Mechanism of action and role in clinical practice
Mathew T. Drake et al.
MAYO CLINIC PROCEEDINGS (2008)
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530
Y-M Chang et al.
ONCOGENE (2008)
Impact of skeletal complications on patients' quality of life, mobility, and functional independence
Luis Costa et al.
SUPPORTIVE CARE IN CANCER (2008)
Osteoclast targeted therapy for prostate cancer: Bisphosphonates and beyond
Matthew R. Smith
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2008)
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
Michael A. Carducci et al.
CANCER (2007)
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer:: a randomised, multicentre, placebo-controlled phase II study
Sten Nilsson et al.
LANCET ONCOLOGY (2007)
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer
Sanjeev Banerjee et al.
CANCER RESEARCH (2007)
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Estimates of the cancer incidence and mortality in Europe in 2006
J. Ferlay et al.
ANNALS OF ONCOLOGY (2007)
Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases
Fred Saad et al.
CLINICAL GENITOURINARY CANCER (2007)
The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer
Claire Morgan et al.
ACTA ONCOLOGICA (2007)
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases
Theresa A. Guise et al.
CLINICAL CANCER RESEARCH (2006)
Targeting bone metastasis in prostate cancer with endothelin receptor antagonists
Michael A. Carducci et al.
CLINICAL CANCER RESEARCH (2006)
Endothelin receptor a blockade enhances taxane effects in prostate cancer
Ardavan Akhavan et al.
NEOPLASIA (2006)
The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model
M Yang et al.
CLINICAL CANCER RESEARCH (2006)
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
G Anderson et al.
BLOOD (2006)
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment
KD Brubaker et al.
BMC CANCER (2006)
Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype
RD Loberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions
RD Loberg et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells
S Nam et al.
CANCER RESEARCH (2005)
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid
A Ullén et al.
ACTA ONCOLOGICA (2005)
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
JG Christensen et al.
CANCER LETTERS (2005)
Bisphosphonates and cancer-induced bone disease:: Beyond their antiresorptive activity
P Clézardin et al.
CANCER RESEARCH (2005)
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer
SJ Kim et al.
CANCER RESEARCH (2005)
Osteoblasts in prostate cancer metastasis to bone
CJ Logothetis et al.
NATURE REVIEWS CANCER (2005)
Src kinase activity is essential for osteoclast function
T Miyazaki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity
ET Keller et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein
JL Dai et al.
CANCER RESEARCH (2004)
Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer
SM Capitosti et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
Differential inhibition of invasion and proliferation by bisphosphonates: Anti-metastatic potential of Zoledronic acid in prostate cancer
R Montague et al.
EUROPEAN UROLOGY (2004)
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
WL Dahut et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation
JP Coxon et al.
BJU INTERNATIONAL (2004)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The role of bisphosphonates in breast and prostate cancers
JE Brown et al.
ENDOCRINE-RELATED CANCER (2004)
Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer
O Sartor et al.
UROLOGY (2004)
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases
JJ Yin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial
MA Carducci et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Src family kinases in tumor progression and metastasis
JM Summy et al.
CANCER AND METASTASIS REVIEWS (2003)
Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting
SY Sung et al.
DIFFERENTIATION (2002)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Metastasis to bone: Causes, consequences and therapeutic opportunities
GR Mundy
NATURE REVIEWS CANCER (2002)
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial
SM Tu et al.
LANCET (2001)
分享论文
